Solifenacin for overactive bladder: secondary analysis of data from VENUS based
on baseline continence status.
Author(s): Toglia MR, Ostergard DR, Appell RA, Andoh M, Fakhoury A, Hussain IF.
Affiliation(s): Urogynecology Associates of Philadelphia, Outpatient Pavilion, Suite 3404, 1098
West Baltimore Pike, Media, PA 19063, USA. togliam@verizon.net
Publication date & source: 2010, Int Urogynecol J. , 21(7):847-54
INTRODUCTION AND HYPOTHESIS: VENUS evaluated the efficacy of solifenacin on
urgency in patients with overactive bladder (OAB). We hypothesized that
solifenacin would be comparably efficacious in continent and incontinent
patients.
METHODS: VENUS was a 12-week, placebo-controlled trial in patients with OAB.
Treatment efficacy was assessed using bladder diaries and patient-reported
outcome measures. The primary endpoint was the change in daily urgency episodes.
Exploratory subgroup analyses were conducted using baseline continence status.
RESULTS: Solifenacin reduced urgency episodes versus placebo in continent (-3.4
vs. -2.3) and incontinent patients (-4.2 vs. -2.9) and incontinence episodes
(-2.1 vs. -1.2) in that subgroup; 58% versus 42% of incontinent patients
receiving solifenacin versus placebo were continent at study end. In both
cohorts, solifenacin- versus placebo-treated patients showed greater improvements
in perceptions of urgency severity, symptom bother, and health-related quality of
life.
CONCLUSION: This post hoc analysis demonstrates the efficacy of solifenacin
regardless of baseline continence status.
|